Literature DB >> 23362175

Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOV-3.

Wiebke Onkes1, Regina Fredrik, Francesca Micci, Benjamin J Schönbeck, Jose I Martin-Subero, Reinhard Ullmann, Felix Hilpert, Karen Bräutigam, Ottmar Janssen, Nicolai Maass, Reiner Siebert, Sverre Heim, Norbert Arnold, Jörg Weimer.   

Abstract

About 20% of ovarian carcinomas show alterations of 19p13 and/or 19q13 in the form of added extra material whose origin often is from chromosome 11. Based on earlier spectral karyotype analysis of the ovarian cancer cell line SKOV-3, which shows an unbalanced translocation der(19)t(11;19), the aim of this study was to determine the precise breakpoints of that derivative chromosome. After rough delimitation of the breakpoints of microdissected derivative chromosomes by array analysis, we designed a matrix of primers spanning 11q13.2 and 19p13.2 detecting multiple amplicons on genomic and cDNA. Sequencing the amplicons, accurate localization of both breakpoints on both chromosomes was possible and we found that exon 14 of HOOK2 from chromosome 19 and exon 2 of ACTN3 from chromosome 11 were fused in the derivative chromosome. The breakpoint in the HOOK2 gene was in an intrinsic triplet of nucleic acids leading to a shift in the ACTN3 reading frame in the derivative chromosome. This frameshift alteration should give rise to an early stop codon causing a loss of function of ACTN3. Signals in two-dimensional Western blotting exactly match to calculated molecular mass and the isoelectric point of the fusion protein.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23362175     DOI: 10.1002/gcc.22048

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  1 in total

1.  Genomic profile of ovarian carcinomas.

Authors:  Francesca Micci; Lisbeth Haugom; Vera M Abeler; Ben Davidson; Claes G Tropé; Sverre Heim
Journal:  BMC Cancer       Date:  2014-05-05       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.